Allogene Therapeutics, Inc. Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value
Allogene Therapeutics, Inc. (ALLO) had Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value of $48.58 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue · last filed 2026-03-12
- 2025-12-31: Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value $48.58M.
- 2024-12-31: Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value $65.78M.
- 2023-12-31: Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value $78.54M.
- 2022-12-31: Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value $10.68M.
| Period end | Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value |
|---|---|
| 2025-12-31 | $48.58M 10-K · filed 2026-03-12 |
| 2024-12-31 | $65.78M 10-K · filed 2026-03-12 |
| 2023-12-31 | $78.54M 10-K · filed 2025-03-13 |
| 2022-12-31 | $10.68M 10-K/A · filed 2024-03-14 |
| 2021-12-31 | $115.87M 10-K/A · filed 2024-03-14 |
| 2020-12-31 | $102.04M 10-K · filed 2022-02-23 |
| 2019-12-31 | $122.90M 10-K · filed 2021-02-25 |
| 2018-12-31 | $61.02M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |